Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/12/2024 | $5.00 | Buy | Craig Hallum |
| 1/20/2023 | Buy → Neutral | BTIG Research | |
| 1/17/2023 | $3.75 | Overweight → Equal-Weight | Stephens |
10-Q - CERUS CORP (0001020214) (Filer)
8-K - CERUS CORP (0001020214) (Filer)
Cerus Corporation (NASDAQ:CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transfusion. "We believe today's recommendation from AK Blut affirms the critical role of pathogen inactivation in protecting patients from transfusion-transmitted bacterial infections. Enhancing patient safety is clearly a key priority of
Cerus Corporation (NASDAQ:CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of the company's website at ir.cerus.com/events-and-presentations/events-and-webcasts/. A replay will be available for 30 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies a
Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
4 - CERUS CORP (0001020214) (Issuer)
Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00
BTIG Research downgraded Cerus from Buy to Neutral
Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h
Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w
Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co
Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen
Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be avai
First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)
SC 13G/A - CERUS CORP (0001020214) (Subject)